Profound thrombocytopenia after primary exposure to eptifibatide

Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,00...

Descripción completa

Detalles Bibliográficos
Autores principales: Norgard, Nicholas B, Badgley, Brian T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108691/
https://www.ncbi.nlm.nih.gov/pubmed/21701628
http://dx.doi.org/10.2147/DHPS.S13239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108691/
https://www.ncbi.nlm.nih.gov/pubmed/21701628
http://dx.doi.org/10.2147/DHPS.S13239

Ejemplares similares